Market
Will Novo Nordisk announce a Wegovy successor trial with improved efficacy by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Novo Nordisk official announcements and press releases
Story
Eli Lilly's Zepbound Achieves 20.2% Weight Loss, Surpassing Wegovy in Head-to-Head Trial
Dec 4, 2024, 02:10 PM
Eli Lilly announced that its obesity drug Zepbound (tirzepatide) has shown superior results to Novo Nordisk's Wegovy (semaglutide) in the first large, head-to-head trial of the two weight-loss medications. The SURMOUNT-5 Phase 3B trial included 751 adults with obesity or overweight, without type 2 diabetes, each having at least one obesity-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Over 72 weeks, patients taking Zepbound lost an average of 20.2% of their body weight (approximately 50.3 lbs or 22.8 kg), compared to a 13.7% weight loss (approximately 33.1 lbs or 15.0 kg) for those on Wegovy. These results indicate that Zepbound provided a 47% greater relative weight loss compared to Wegovy, highlighting its potential as a more effective treatment for obesity.
View original story
Similar markets
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Falls short of expectations • 25%
Trial cancelled • 25%
Meets expectations • 25%
Exceeds expectations • 25%
Pursue mergers or acquisitions • 25%
Focus on improving CagriSema • 25%
Increase investment in marketing existing drugs • 25%
Develop a new obesity drug • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Kidney disease • 25%
Heart disease • 25%
Brain disorders • 25%
Stroke • 25%
Weight loss < 17.5% • 25%
Weight loss > 20.7% • 25%
Weight loss between 19% and 20.7% • 25%
Weight loss between 17.5% and 19% • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
No action taken • 25%